Back to Search Start Over

Biosynthesis of folic acid appended PHBV modified copper oxide nanorods for pH sensitive drug release in targeted breast cancer therapy.

Authors :
Singh, Swati
Ghosh, Chandrachur
Roy, Partha
Pal, Kaushik
Source :
International Journal of Pharmaceutics. Jun2022, Vol. 622, pN.PAG-N.PAG. 1p.
Publication Year :
2022

Abstract

[Display omitted] • pH-sensitive biocompatible paclitaxel loaded multifunctional nanosystem was formulated. • The in vitro drug release profile results demonstrated a faster paclitaxel release from the nanosystem at pH 5.0 compared to pH 7.4. • FA binding to the folate receptor in cancer cells facilitated better targeted delivery. • Combination of paclitaxel and metal oxide nanoparticle provide a novel approach for cancer treatment. Multifunctional nanoplatforms as nanocarriers have attracted the interest of many scientists because they can achieve greater therapeutic effect in anticancer drug delivery to tumors with potential to improve cancer treatment, while currently available therapies are nonspecific and ineffectual. In present study, notable cancer therapeutic strategy which combines PEG functionalized poly (3-hydroxybutyric acid-co-hydroxyvaleric acid) (PHBV) nanospheres decorated with folic acid for delivery of paclitaxel (PTX) drug conjugated with copper oxide (CuO) nanoparticles (NPs) is proposed. Moreover, PTX loading with CuO NPs in PHBV nanosphere was done to increase its solubility and analyze its apoptotic effects in human breast cancer (MCF-7) cells. The pH-sensitive CuO-PTX@PHBV-PEG-FA nanosystem was successfully developed, as evidenced by number of characterizations. Resultant CuO-PTX@PHBV-PEG-FA NPs were 148.93 ± 10.5 nm in size, having 0.206 PDI, with −20.3 ± 0.6 mV zeta potential. MTT assay in MCF-7 cells was used to assess cell viability, while anticancer potential of CuO-PTX@PHBV-PEG-FA nanosystem was confirmed through different staining techniques. According to in vitro studies, FA-conjugated PHBV modified CuO-PTX targeted nanoparticles exhibited higher anticancer effect than free PTX probably due to binding interaction of folate receptor with cells that overexpress the target. This nanosystem has the potential to be a promising breast cancer treatment agent. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03785173
Volume :
622
Database :
Academic Search Index
Journal :
International Journal of Pharmaceutics
Publication Type :
Academic Journal
Accession number :
157498726
Full Text :
https://doi.org/10.1016/j.ijpharm.2022.121831